Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
OppFi Reaffirms 2026 Adjusted EPS Guidance of $1.34-$1.40

OppFi Reaffirms 2026 Adjusted EPS Guidance of $1.34-$1.40

BitgetBitget2026/11/03 13:32
  • OppFi reaffirmed full-year 2026 revenue guidance of $600 million to $610 million.
  • Adjusted net income is expected at $115 million to $120 million.
  • Adjusted EPS guidance remains $1.34 to $1.40, based on approximately 86 million weighted average diluted shares.
  • The reaffirmation accompanied the withdrawal of federal banking regulatory applications for the proposed BNC acquisition, citing unclear regulatory standards.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OppFi Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030830PR_NEWS_USPR_____CG87392) on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss